L-Carnitine: How the Heart Gets Its Preferred Fuel
The heart runs mostly on fat, and fat cannot enter a mitochondrion without a carrier.
What does L-carnitine do for the heart?
L-carnitine transports long-chain fatty acids across the inner mitochondrial membrane so they can undergo beta-oxidation. Cardiac muscle derives the majority of its energy from fatty acid oxidation, making carnitine availability directly relevant to cardiac energy production. A systematic review in Mayo Clinic Proceedings examined L-carnitine in secondary cardiovascular prevention.
The transport problem
Mitochondria generate ATP by oxidising fuel, but the inner mitochondrial membrane is selectively permeable and long-chain fatty acids cannot cross it unaided.
The carnitine shuttle solves this. Fatty acids are attached to carnitine to form acylcarnitine, which is transported across the membrane, and the fatty acid is released inside for beta-oxidation. Carnitine returns to repeat the cycle.
Without adequate carnitine, fatty acids accumulate in the cytoplasm unable to reach the machinery that would burn them. The fuel is present and inaccessible.
Why the heart cares more than most tissues
Cardiac muscle derives the majority of its ATP from fatty acid oxidation under normal conditions — commonly cited around sixty to seventy percent, with glucose and lactate making up the rest.
This makes the carnitine shuttle directly rate-limiting for cardiac energy production in a way it is not for tissues that run primarily on glucose.
Cardiac tissue accordingly maintains high carnitine concentrations. Reduced myocardial carnitine has been documented in some cardiac conditions, which is the basis for interest in supplementation.
What the trials examined
A systematic review and meta-analysis published in Mayo Clinic Proceedings examined L-carnitine in the secondary prevention of cardiovascular disease, pooling trials in patients following myocardial infarction and looking at mortality, arrhythmia and angina endpoints.
Other trials have examined exercise tolerance and symptom measures in heart failure and in peripheral arterial disease.
The consistent caveat across this literature is the same as with CoQ10 and hawthorn: the evidence sits in populations with established cardiac dysfunction or documented carnitine depletion. Evidence in healthy adults with adequate carnitine status is much thinner, and the deficiency-correction pattern applies here as elsewhere.
L-carnitine is one of four CardioEaseX actives
Alongside CoQ10, hawthorn berry and magnesium, supporting cardiac energetics and output.
Dietary carnitine
The body synthesises carnitine from lysine and methionine, requiring vitamin C, B6, niacin and iron as cofactors. Endogenous synthesis covers most requirements in most people.
Dietary carnitine comes overwhelmingly from animal products, particularly red meat — the name derives from the Latin for flesh. Vegetarians and vegans have measurably lower plasma and tissue carnitine, though they typically synthesise adequately.
Absorption of dietary carnitine is efficient at around 54 to 87 percent. Absorption of supplemental carnitine is considerably lower, roughly 14 to 18 percent, which is worth knowing when comparing doses across sources.
The TMAO question
This deserves addressing rather than ignoring, because it is a genuine line of research.
Gut bacteria metabolise carnitine to trimethylamine, which the liver converts to trimethylamine N-oxide (TMAO). Elevated TMAO has been associated with cardiovascular risk in observational studies, creating an apparent paradox: a supplement taken for cardiac benefit producing a metabolite associated with cardiac risk.
The picture is unresolved. Whether TMAO is causal or a marker remains debated. Gut microbiome composition strongly influences how much TMAO is produced from a given carnitine intake. And the intervention trials on carnitine and cardiac outcomes were conducted with TMAO production presumably occurring, yet still reported the endpoints they did.
The honest position is that this is an open question rather than a settled objection or a resolved non-issue. Anyone telling you it is definitively one or the other is overstating the state of the evidence.
Practical notes
- L-carnitine tartrate and acetyl-L-carnitine are common forms; the latter crosses the blood-brain barrier more readily and appears more often in cognitive contexts.
- D-carnitine is not useful and can interfere with the L-form. Products should specify L.
- Thyroid medication. Carnitine may reduce thyroid hormone action; relevant if you take levothyroxine.
- Seizure disorders. Some reports of increased seizure frequency; discuss with your neurologist.
- Renal impairment. Requires medical guidance.
